Clinical Trials

Spherix meets overseas CRO, moves to finalize phase 3 trial of Naturlose for diabetes

Published in Diabetes Week, April 17th, 2006

Spherix Incorporated (SPEX) announced that its CEO, its BioSpherix Division research manager, and its consultant, Environ International, Inc., returned from overseas meetings with staff members and inspected facilities of a clinical research organization.

An agreement for a multinational phase 3 clinical trial of Spherix's Naturlose as a type 2 diabetes drug is being finalized. Preliminary work is underway and patient recruitment is expected to begin before year-end.

Last November, the U.S. Food and Drug Administration (FDA) approved the phase 1 and phase 2 clinical trial data submitted by Spherix, and authorized the Phase 3 clinical trial in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Diabetes Week

Source: Diabetes Week (2006-04-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry